AllianceBernstein’s CRISPR Therapeutics CRSP Stock Holding History

AllianceBernstein’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.05M	Hold	96,357	–	–	﹤0.01%	1541
2025 Q4	$5.05M	Buy	96,357 +10,023	+12%	+$600K	﹤0.01%	1536
2025 Q3	$5.6M	Sell	86,334 -286	-0.3%	-$16.4K	﹤0.01%	1464
2025 Q2	$4.21M	Buy	+86,620	New	+$3.35M	﹤0.01%	1556
2021 Q3	–	Sell	-1,439	Closed	-$233K	–	3297
2021 Q2	$233K	Sell	1,439 -580	-29%	-$70.5K	﹤0.01%	3108
2021 Q1	$246K	Buy	2,019 +700	+53%	+$106K	﹤0.01%	2986
2020 Q4	$202K	Buy	+1,319	New	+$156K	﹤0.01%	2992
2019 Q1	–	Sell	-60,400	Closed	-$1.73M	–	3119
2018 Q4	$1.73M	Buy	+60,400	New	+$2.1M	﹤0.01%	1905

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein's CRSP Position: Q1 2026 in Review

AllianceBernstein held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 96,357 shares worth $5.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1541.

AllianceBernstein first reported a position in CRSP in Q4 2018 and has held it in 8 quarters since. The position peaked at $5.6M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

AllianceBernstein held 96,357 shares of CRISPR Therapeutics worth $5.05M as of Q1 2026.
AllianceBernstein left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1541 holding.
AllianceBernstein first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 8 quarters since.
AllianceBernstein's CRISPR Therapeutics position peaked at $5.6M in Q3 2025.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.